Postmenopausal osteoporosis: Primary prevention or excessive use of medications;Osteoporosis posmenopáusica: Prevención primaria o medicación excesiva

Semergen

Volumn 39, Issue 3, 2013, Pages 123-129

  Mendoza Edroso, C ^a   Sanchez Garrido Lestache N ^a   Lopez Picado, A ^b  

^a Medicina de Familia y Comunitaria Servicio de Urgencias y Emergencias 061   (Spain)

^b HOSPITAL TXAGORRITXU   (Spain)

Author keywords

Medication; Menopause; Osteoporosis; Women

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ORGANOMETALLIC COMPOUND; RALOXIFENE; STRONTIUM RANELATE; THIOPHENE DERIVATIVE;

AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG UTILIZATION; FEMALE; HUMAN; MIDDLE AGED; POSTMENOPAUSE OSTEOPOROSIS; PRIMARY PREVENTION; STATISTICS;

AGED; CROSS-SECTIONAL STUDIES; DIPHOSPHONATES; DRUG UTILIZATION; FEMALE; HUMANS; MIDDLE AGED; ORGANOMETALLIC COMPOUNDS; OSTEOPOROSIS, POSTMENOPAUSAL; PRIMARY PREVENTION; RALOXIFENE; THIOPHENES;

EID: 84875685783     PISSN: 11383593     EISSN: 15788865     Source Type: Journal    
DOI: 10.1016/j.semerg.2012.07.006     Document Type: Article

References (28)

1. GEIOS Guía de práctica clínica osteoporosis 2010, Multimédica proyectos, Madrid.
2. Osteoporosis posmenopáusica. Guía de Práctica Clínica. Rev Clin Esp 2003, 203:496-506. Grupo de trabajo de la SEIOMM.
3. Vestergaard P., Mosekilde L., Langdahl B. Fracture prevention in postmenopausal women. Clin Evid 2011, 2011:1109.
4. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. The Lancet 2002, 359:1929-1936.
5. Unnanuntana A., Gladnick B.P., Donelly E., Lane J.M. The Assessment of Fracture Risk. J Bone Joint Surg 2010, 92:743-753.
6. Kanis J.A., Johnell O., Oden A., Johansson H., McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397.
7. Kanis J.A., McCloskey E.V., Johansson H., Strom O., Borgstrom F., Oden A., et al. Case finding for the management of osteoporosis with FRAX assesment and intervention threesholds for the UK. Osteoporos Int 2008, 19:1395-1408. National Osteoporosis Guideline Group.
8. Kanis J.A., Burlet N., Cooper C., Delmas P.D., Reginster J.Y., Borgstrom F., et al. Guía europea para el diagnóstico y tratamiento de la osteoporosis en la mujer posmenopáusica. Osteoporos Int 2008, 19:399-428.
9. NAMS Management of osteoporosis in postmenopausal women:2010 position statement of North American Menopause Society. Menoapuse 2010, 17:5-54.
10. Fisterra. GPC Osteoporosis [consultado 12 Feb 2012]. Disponible en . http://www.fisterra.com/guias-clinicas/osteoporosis/.
11. National Guidelines for Osteoporosis Management 2008, National Osteoporosis Fundation, National Osteoporosis Foundation, Washington.
12. MacLean C., Newberry S., Maglione M., McMahon M., Ranganath V., Suttorp M., et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008, 148:197-213.
13. NICE technology appraisal guidance Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women 2010, National Institute for Health, Clinical Excellence, National Institute for Health and Clinical Excellence, London.
14. Cranney A. Biphosphonates - Treatment of Osteoporosis. Pathophys Clin Managem Contem Endocrinol 2010, 469-486.
15. Wells G.A., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rew 2008, CD001155.
16. Wells G., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rew 2008, CD004523.
17. Wells G., Cranney A., Peterson J., Boucher M., Shea B., Robinson V., et al. Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev 2008, CD003376.
18. O'Donnell S., Cranney A., Wells G.A., Adachi J.D., Reginster J.Y. Strontium ranelate for preventing and treating postmenopausal osteoporosis. Cochrane Database Syst Rev 2006, CD005326.
19. Ensrud K.E., Stock J.L., Barrett-Connor E., Grady D., Mosca L., Khaw K.T., et al. Effects of raloxifene on fracture risk in postmenopausal women: the raloxifene use for the heart trial. J Bone Miner Res 2008, 23:112-120.
20. Abrahamsen B. Bisphosphonate adverse effects lessons from large databases. Curr Opin Rheumatol 2010, 22:363-470.
21. Kennel K.A., Drake M.T. Adverse effects of bisphosphonates: implications for osteoporosis management. Mayo Clin Proc 2009, 84:632-637.
22. Sweet M.G., Sweet J.M., Jeremiah M.P., Galazka S.S. Diagnosis and treatment of osteoporosis. Am Fam Physician 2009, 78:193-200.
23. De Felipe R., Caceres C., Cimas M., Dávila G., Fernandez S., Ruiz T. Características clínicas de los pacientes con tratamiento para la osteoporosis en un centro de Atención Primaria: ¿a quién tratamos en nuestras consultas?. Aten Primaria 2010, 42:559-563.
24. Arana-Arri E., Gutiérrez-Ibarluzea I., Gutiérrez Ibarzabal M.L., Ortueta Chamorro P., Giménez Robredo A.I., Sánchez Mata A.M., et al. Análisis comparativo frente a la evidencia del manejo de la osteoporosis en una comarca de atención primaria. Aten Primaria 2008, 40:549-554.
25. Amaya M.C., Gomez M.M., Martinez M.J., Lendinez J.M. Adecuación del tratamiento preventivo de fracturas osteoporóticas en mujeres posmenopáusicas. SEMERGEN 2010, 36:121-127.
26. Zwart Salmerón M., Fradera Vilalta M., Solanas Saura P., Gonzalez Pastor C., Adalid Vilar C. Abordaje de la osteoporosis en un centro de atención primaria. Aten Primaria 2004, 33:183-187.
27. Gómez Navarro R. Aplicación de la herramienta FRAX para la determinación del riego de fractura en mujeres de un ámbito real. Rev Esp Salud Pública 2010, 84:321-330.
28. Roig Vilaseca D., Gomez Vaquero C., Hoces Otero C., Nolla J.M. Riesgo de fractura calculado con el índice FRAX en pacientes con osteoporosis tratados y no tratados. Med Clín (Barc) 2010, 13:189-193.